An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19

Dafydd R. Owen, Charlotte M. N. Allerton, Annaliesa S. Anderson, Lisa Aschenbrenner, Melissa Avery, Simon Berritt, Britton Boras, Rhonda D. Cardin, Anthony Carlo, Karen J. Coffman, Alyssa Dantonio, Li Di, Heather Eng, RoseAnn Ferre, Ketan S. Gajiwala, Scott A. Gibson, Samantha E. Greasley, Brett L. Hurst, Eugene P. Kadar, Amit S. Kalgutkar, Jack C. Lee, Jisun Lee, Wei Liu, Stephen W. Mason, Stephen Noell, Jonathan J. Novak, R. Scott Obach, Kevin Ogilvie, Nandini C. Patel, Martin Pettersson, Devendra K. Rai, Matthew R. Reese, Matthew F. Sammons, Jean G. Sathish, Ravi Shankar P. Singh, Claire M. Steppan, Al E. Stewart, Jamison B. Tuttle, Lawrence Updyke, Patrick R. Verhoest, Liuqing Wei, Qingyi Yang, Yuao Zhu
doi: https://doi.org/10.1101/2021.07.28.21261232

Article Information

doi 
https://doi.org/10.1101/2021.07.28.21261232
History 
  • July 31, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Dafydd R. Owen1,*,
  2. Charlotte M. N. Allerton1,
  3. Annaliesa S. Anderson2,
  4. Lisa Aschenbrenner3,
  5. Melissa Avery3,
  6. Simon Berritt3,
  7. Britton Boras4,
  8. Rhonda D. Cardin2,
  9. Anthony Carlo3,
  10. Karen J. Coffman3,
  11. Alyssa Dantonio3,
  12. Li Di3,
  13. Heather Eng3,
  14. RoseAnn Ferre4,
  15. Ketan S. Gajiwala4,
  16. Scott A. Gibson5,
  17. Samantha E. Greasley4,
  18. Brett L. Hurst5,
  19. Eugene P. Kadar3,
  20. Amit S. Kalgutkar1,
  21. Jack C. Lee3,
  22. Jisun Lee3,
  23. Wei Liu4,
  24. Stephen W. Mason2,†,
  25. Stephen Noell3,
  26. Jonathan J. Novak3,†,
  27. R. Scott Obach3,
  28. Kevin Ogilvie3,
  29. Nandini C. Patel1,
  30. Martin Pettersson1,§,
  31. Devendra K. Rai2,
  32. Matthew R. Reese3,
  33. Matthew F. Sammons1,
  34. Jean G. Sathish2,
  35. Ravi Shankar P. Singh1,
  36. Claire M. Steppan3,
  37. Al E. Stewart4,
  38. Jamison B. Tuttle1,
  39. Lawrence Updyke1,
  40. Patrick R. Verhoest1,
  41. Liuqing Wei3,
  42. Qingyi Yang1 and
  43. Yuao Zhu2
  1. 1Pfizer Worldwide Research, Development & Medical; Cambridge, MA 02139, USA
  2. 2Pfizer Worldwide Research, Development & Medical; Pearl River, NY 10965, USA
  3. 3Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA
  4. 4Pfizer Worldwide Research, Development & Medical; La Jolla, CA 92121, USA
  5. 5Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University; Logan, UT 84322, USA
  1. ↵*Corresponding author. Email: Dafydd.owen{at}pfizer.com

  • ↵† Present address: Janssen Biopharma; South San Francisco, CA 94080.

  • ‡ Present address: Praxis Precision Medicines; Cambridge, MA 02142.

  • ↵§ Present address: GRT Therapeutics; Cambridge, MA 02142.

Back to top
Posted July 31, 2021.
Download PDF
Data/Code
Email
An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19
Dafydd R. Owen, Charlotte M. N. Allerton, Annaliesa S. Anderson, Lisa Aschenbrenner, Melissa Avery, Simon Berritt, Britton Boras, Rhonda D. Cardin, Anthony Carlo, Karen J. Coffman, Alyssa Dantonio, Li Di, Heather Eng, RoseAnn Ferre, Ketan S. Gajiwala, Scott A. Gibson, Samantha E. Greasley, Brett L. Hurst, Eugene P. Kadar, Amit S. Kalgutkar, Jack C. Lee, Jisun Lee, Wei Liu, Stephen W. Mason, Stephen Noell, Jonathan J. Novak, R. Scott Obach, Kevin Ogilvie, Nandini C. Patel, Martin Pettersson, Devendra K. Rai, Matthew R. Reese, Matthew F. Sammons, Jean G. Sathish, Ravi Shankar P. Singh, Claire M. Steppan, Al E. Stewart, Jamison B. Tuttle, Lawrence Updyke, Patrick R. Verhoest, Liuqing Wei, Qingyi Yang, Yuao Zhu
medRxiv 2021.07.28.21261232; doi: https://doi.org/10.1101/2021.07.28.21261232
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area